angiogenesis inhibitors

Aflibercept - Bevacizumab - Cediranib - Motesanib - Sorafenib - Vandetanib      

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

advanced breast cancer (metastatic)

bevacizumab
RIBBON-I (Robert) on top capecitabine, 2009bevacizumab + capecitabinecapecitabine 1st line suggesting
AVF2119g (Miller) cape, 2005bevacizumab + capecitabinecapecitabine 2nd line Risk of bias suggesting
RIBBON-2 (Brufsky), 2009bevacizumav + CTCT alone 2nd line suggesting
AVADO (Miles) 15mg , 2009bevacizumab + docetaxeldocetaxel 1st line HER-2 negative suggesting
AVADO (Miles) 7.5mg, 2010bevacizumab + docetaxeldocetaxel 1st line HER-2 negative negative
Burstein, 2005bevacizumab + methotrexatemethotrexatenegative
Martin bevacizumab, 2011bevacizumab + paclitaxelpaclitaxel 1st line HER-2 negative negative
E2100 (Miller), 2007bevacizumab + taxanestaxanes 1st line NCT00028990Risk of bias suggesting
RIBBON-I (Robert) on top Tax or anthra, 2009bevacizumab + taxanestaxanes 1st line suggesting
ceritinib
Hyamscediranib + fulvestrantfulvestrantNCT00454805 -
motesanib
Martin (motesanib), 2011motesanib + paclitaxelpaclitaxel 1st line HER-2 negative NCT00356681 -
sorafenib
RESILIENCE, 2013 ongoing sorafenib + capecitabinecapecitabine alone ongoing
Schwartzberg, 2013sorafenib + gemcitabine or capecitabinegemcitabine or capecitabine alone 2nd line HER-2 negative NCT00493636Exploratory suggesting
Gradishar, 2013sorafenib + paclitaxelpaclitaxel alone 1st line HER-2 negative Exploratory negative

lung cancer (metastatic)

aflibercept
Ramlau, 2012Aflibercept and Docetaxel Docetaxel -
bevacizumab
Reck, 2010bevacizumab -
Sandler, 2006bevacizumab -
Johnson, 2004bevacizumab -
Nishio, 2009bevacizumab -
Herbst, 2007bevacizumab -
Herbst, 2011bevacizumab -
ceritinib
Laurie, 2014cediranib carboplatin and paclitaxel -
Goss, 2010cediranib carboplatin and paclitaxel -
Dy, 2013cediranib gemcitabine and carboplatin -
motesanib
Scagliottib MONET1, 2012motesanib plus carboplatin/paclitaxel -
pazopanib
Scagliotti, 2013pazopanib pemetrexed -
sorafenib
Wakelee, 2012sorafenib -
Paz-Ares, 2012sorafenib -
Spigel, 2011sorafenib and erlotinib erlotinib -
Scagliotti, 2010sorafenibplacebo -
sunitinib
Groen, 2013sunitinib erlotinib -
Scagliottia, 2012Sunitinib plus erlotinib erlotinib -
Heist CALGB 30704 (Alliance): , 2014sunitinib pemetrexed -
vandetanib
Aisner, 2013vandetanib -
Ahn, 2013vandetanib maintenance -
de Boer, 2011Vandetanib plus pemetrexed -
Natale, 2009Vandetanib versus gefitinib -
Natale, 2011Vandetanib gefitinib -
Lee ZEPHYR, 2012Vandetanib placebo -
Heymach, 2007 vandetanib plus docetaxel placebo plus docetaxel -

renal-cell carcinoma (advanced)

bevacizumab
CALGB 90206, 2010bevacizumab plus interferon alfainterferon alphasuggesting
AVOREN, 2007bevacizumab plus interferon alfainterferon alphasuggesting
Yang, 2003bevacizumabplaceboExploratory -